ONCAlert | Upfront Therapy for mRCC

Proton Therapy for Recurrent Glioma

Jeffrey J. Raizer, MD
Published Online: 8:30 PM, Thu November 20, 2014
Jeffrey J. Raizer, MD, Co-Director, Northwestern Brain Tumor Institute, Professor in Neurology, Ken and Ruth Davee Department, Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, provides an overview of a study that analyzed the overall survival and toxicity profile of proton therapy for large-volume re-irradiation for patients with recurrent glioma.

Clinical Pearls

  1. The study looked at patients who failed bevacizumab or standard therapy. Proton therapy was used in addition to bevacizumab and temozolomide with the idea that re-irradiating the volume might result in less toxicity.
  2. Though the study only enrolled a small number of patients, this approach looks beneficial.
  3. Patients on the trial survived for 6-7 months, when the standard is typically 2-3 months. This approach elicited no additional toxicity.

<<< View more from the 2014 SNO meeting

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.